• 855-853-4760
  • customerservice@arevapharma.com

Temozolomide

Temozolomide

Temozolomide is an alkylating agent indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a type of primary brain cancer, for which it is given concomitantly with radiotherapy and then as maintenance treatment. Temozolomide is also indicated for the treatment of refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine; anaplastic astrocytoma is a type of cancer that can occur within the brain and spinal cord.

Temozolomide capsules should not be opened or chewed. They should be swallowed whole with a glass of water.

Products Infomation
RX PRODUCT NDC# STRENGTH SIZE PRODUCT CLASS ADMINISTRATION CASE SIZE
Temozolomide 59923-707-05 100 mg 5 capsules per single bottle Antineoplastic Oral Capsule 12 bottles
Temozolomide 59923-708-14 100 mg 14 capsules per single bottle Antineoplastic Oral Capsule 12 bottles
Temozolomide 59923-709-05 140 mg 5 capsules per single bottle Antineoplastic Oral Capsule 12 bottles
Temozolomide 59923-710-14 140 mg 14 capsules per single bottle Antineoplastic Oral Capsule 12 bottles
Temozolomide 59923-711-05 180 mg 5 capsules per single bottle Antineoplastic Oral Capsule 12 bottles
Temozolomide 59923-712-14 180 mg 14 capsules per single bottle Antineoplastic Oral Capsule 12 bottles
Temozolomide 59923-713-05 250 mg 5 capsules per single bottle Antineoplastic Oral Capsule 12 bottles
Wholesaler Temozolomide 100mg /5 cap Temozolomide 100mg 14 cap Temozolomide 140mg 5 cap Temozolomide 140mg 14 cap Temozolomide 180mg 5 cap Temozolomide 180mg 14 cap Temozolomide 250mg 5 cap
AmerisourceBergen 10218692 10218696 10218681 10218690 10218693 10218680 10218695
Cardinal 5550314 5550322 5550330 5550348 5550355 5550363 5550371
Mckenson 3909124 3799715 3799855 3903010 3902988 3902970 3799822